Immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologic drugs

J Eur Acad Dermatol Venereol. 2022 Apr;36(4):e266-e268. doi: 10.1111/jdv.17861. Epub 2021 Dec 17.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Viral
  • BNT162 Vaccine
  • Biological Products*
  • COVID-19 Vaccines / adverse effects
  • COVID-19* / prevention & control
  • Humans
  • Psoriasis* / drug therapy

Substances

  • Antibodies, Viral
  • Biological Products
  • COVID-19 Vaccines
  • BNT162 Vaccine